Key result
Approved PAH therapies reduce morbidity and mortality events ~40% in functional class I/II patients.
Why the study?
Limited data were available regarding the long-term prognosis and response to therapy in pulmonary arterial hypertension patients with World Health Organization functional class I/II symptoms.
What is the long-term survival of patients with pulmonary arterial hypertension in WHO functional class I/II in observational registries, and do approved PAH medical therapies reduce morbidity and mortality clinical events in this population in randomized controlled trials?
Meta-Analysis (n=9,062)
Yes
What is the long-term survival of patients with pulmonary arterial hypertension in WHO functional class I/II in observational registries, and do approved PAH medical therapies reduce morbidity and mortality clinical events in this population in randomized controlled trials?
Patients with WHO functional class I or II pulmonary arterial hypertension still face a substantial 22% three-year mortality risk, and approved PAH medical therapies reduce their risk of morbidity and mortality events by 40%, supporting early optimization of therapy and multiparameter risk assessment.
Answers are grounded in this paper and cite their sources.
Supports early therapy optimization in functional class I/II PAH; confirms morbidity-mortality benefit in this population.
Limited data about the long‐term prognosis and response to therapy in pulmonary arterial hypertension patients with World Health Organization functional class I/II symptoms are available. PubMed and Embase were searched for publications of observational registries and randomized, controlled trials in pulmonary arterial hypertension patients published between January 2001 and January 2018. Eligible registries enrolled pulmonary arterial hypertension patients ≥18 years, N > 30, and reported survival by functional class. Randomized, controlled trial inclusion criteria were pulmonary arterial hypertension patients ≥18 years, ≥6 months of treatment, and morbidity, mortality, or time to worsening as end points reported by functional class. The primary outcomes were survival for registries and clinical event rates for randomized, controlled trials. Separate random effects models were calculated for registries and randomized, controlled trials. Four randomized, controlled trials ( n = 2482) and 10 registries ( n = 6580) were included. Registries enrolled 9%–47% functional class I/II patients (the vast majority being functional class II) with various pulmonary arterial hypertension etiologies. Survival rates for functional class I/II patients at one, two, and three years were 93% (95% confidence interval (CI): 91%–95%), 86% (95% CI: 82%–89%), and 78% (95% CI: 73%–83%), respectively. The hazard ratio for the treatment effect in randomized, controlled trials overall was 0.61 (95% CI: 0.51–0.74) and 0.60 (95% CI: 0.44–0.82) for functional class I/II patients and 0.62 (95% CI: 0.49–0.78) for functional class III/IV. The calculated risk of death of 22% within three years for functional class I/II patients underlines the need for careful assessment and optimal treatment of patients with functional class I/II disease. The randomized, controlled trial analysis demonstrates that current medical therapies have a beneficial treatment effect in this population.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2020) conducted a meta-analysis in Pulmonary arterial hypertension (PAH) (n=9,062). Approved PAH medical therapies (in RCTs) and WHO Functional Class I/II vs III/IV status (in registries) vs. Placebo or comparator control arm (with or without background PAH therapy) was evaluated on Morbidity or mortality clinical event in WHO functional class I/II patients (RCT meta-analysis) (HR 0.60, 95% CI 0.44-0.82). Approved PAH therapies reduced morbidity and mortality events by 40% in functional class I/II patients, who face a 22% 3-year mortality risk in registries.
Synapse has enriched 10 related papers. Consider them for comparative context: